Click Therapeutics, Inc. and UK-based pharmaceutical company Indivior plc announced a collaboration to develop and commercialize a prescription digital therapeutics for treating substance use disorders, starting with opioid use disorder.
Click Therapeutics And Indivior Collaborate On Prescription Digital Therapeutics In Substance Use Disorder
Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.
